NYSE$PLX
Protalix Biotherapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Protalix reported an increase in revenue from selling goods, offset by a decrease in R&D revenue, and a net loss for Q3 2021.
Protalix BioTherapeutics reported its Q3 2021 financial results, showing an increase in revenues from selling goods by 36% compared to the same period in 2020. Revenues from license and R&D services remained consistent. The company's net loss for the quarter was $4.2 million, slightly better than the $4.4 million loss in Q3 2020. The company is progressing with its regulatory submissions for PRX-102 and has sufficient capital to fund operations through milestones in 2022.
- Revenues from selling goods increased by 36% to $4.5 million compared to Q3 2020.
- Revenues from license and R&D services were $7.5 million.
- Net loss for the quarter was $4.2 million, an improvement from the $4.4 million loss in Q3 2020.
- The company anticipates resubmitting the PRX-102 BLA to the FDA in the second half of 2022 and submitting an MAA to the EMA in the first quarter of 2022.
Headline financials
Revenue & EPS history
Protalix · Revenue · Quarterly
$12.1M
Revenue by segment
Protalix · $3.18M total across 1 segment · Q2 2021
- License & R&D$3.18M—100.0%
Forward guidance
Protalix anticipates resubmitting the PRX-102 BLA to the FDA in the second half of 2022 and submitting an MAA to the EMA in the first quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-1.3%
Avg return
Earnings day
-1.7%
Avg return
5 days after
-5.6%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+15.7%
Q2 2023
Best reaction
-36.4%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +0.0% | +9.5% | |
| Q4 2025 | +1.8% | -23.7% | -16.8% | |
| Q3 2025 | -10.9% | -12.1% | -16.4% | |
| Q1 2025 | +0.0% | +2.4% | -10.8% | |
| Q4 2024 | +9.4% | +11.2% | +16.1% | |
| Q3 2024 | +12.9% | +31.5% | +45.2% | |
| Q2 2024 | -8.7% | -7.7% | +1.0% | |
| Q1 2024 | -8.8% | -9.6% | -10.4% | |
| Q4 2023 | -12.5% | -14.5% | -22.4% | |
| Q3 2023 | -18.9% | -27.6% | -14.1% | |
| Q2 2023 | +15.7% | +15.7% | +13.9% | |
| Q1 2023 | +3.8% | -7.3% | -29.8% | |
| Q4 2022 | +6.6% | +12.6% | +11.0% | |
| Q3 2022 | +0.9% | +1.9% | +10.5% | |
| Q2 2022 | -0.4% | -2.4% | -11.4% | |
| Q1 2022 | +0.9% | +7.5% | +1.9% | |
| Q4 2021 | +0.0% | +40.0% | +10.5% | |
| Q3 2021 | -3.5% | -14.0% | -21.9% | |
| Q2 2021 | +2.2% | +0.0% | -0.7% | |
| Q1 2021 | +0.7% | -1.0% | -24.4% | |
| Q4 2020 | -5.1% | -4.5% | -24.7% | |
| Q3 2020 | -7.9% | -9.3% | +2.0% | |
| Q2 2020 | +2.2% | +3.3% | -6.1% | |
| Q1 2020 | +2.7% | +7.5% | +12.3% | |
| Q4 2019 | -3.0% | -5.1% | +3.8% | |
| Q3 2019 | -5.2% | -8.7% | +34.8% | |
| Q2 2019 | -36.4% | -29.7% | -40.5% | |
| Q1 2019 | -2.7% | -6.8% | -15.9% | |
| Q4 2018 | +1.8% | -6.1% | -12.2% | |
| Q3 2018 | -5.2% | -14.3% | -12.2% | |
| Q2 2018 | -2.0% | +0.0% | -6.0% | |
| Q1 2018 | +2.2% | +12.5% | +15.0% | |
| Q4 2017 | -1.4% | +1.5% | -33.8% | |
| Q3 2017 | -6.6% | -1.4% | -15.1% | |
| Q2 2017 | -4.6% | -12.3% | -4.6% | |
| Q1 2017 | -6.0% | -13.0% | -5.4% | |
| Q4 2016 | -4.7% | -14.1% | -18.0% | |
| Q3 2016 | +12.1% | +34.1% | -26.8% | |
| Q2 2016 | -1.5% | -1.6% | -4.7% | |
| Q1 2016 | -0.6% | — | — | |
| Q4 2015 | +4.7% | — | — | |
| Q3 2015 | -3.8% | — | — | |
| Q2 2015 | +3.8% | — | — | |
| Q1 2015 | +1.4% | — | — | |
| Q4 2014 | -5.4% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -1.3% | — | — | |
| Q1 2014 | -0.5% | — | — | |
| Q4 2013 | -2.5% | — | — | |
| Q3 2013 | +0.2% | — | — | |
| Q2 2013 | +4.3% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | +4.0% | — | — | |
| Q3 2012 | +1.3% | — | — | |
| Q2 2012 | +1.4% | — | — | |
| Q1 2012 | +2.8% | — | — | |
| Q4 2011 | -1.5% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q2 2011 | -9.7% | — | — | |
| Q1 2011 | -0.8% | — | — | |
| Q4 2010 | -1.3% | — | — | |
| Q3 2010 | -4.4% | — | — | |
| Q2 2010 | +0.1% | — | — | |
| Q1 2010 | +6.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro